← Oncology Approval Tracker

FDA DECISION ·

Welireg

belzutifan · Merck

FDA approvalNew therapyVon Hippel-Lindau-associated tumors
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

Adults with von Hippel-Lindau disease who need treatment for associated renal cell carcinoma, central nervous system hemangioblastomas or pancreatic neuroendocrine tumors when immediate surgery is not required.

LAMPGEN ANALYSIS

Why it matters

The decision introduces HIF-2α inhibition for selected VHL-associated tumors.

What research teams should watch

Record the affected organs and surgical urgency and coordinate lesion imaging, anemia and oxygenation follow-up.

PRIMARY RECORDS

Sources